D.M., J.A.P., R.B.S. and V.E.V. are inventors on patent applications submitted by Johns Hopkins University related to cell-free DNA for cancer detection. P.B.B. is an employee of Delfi Diagnostics, scientific advisor for EQRx and director of OncoHealth. J.A.P. and R.B.S. are founders of Delfi Diagnostics. V.E.V. is a founder of Delfi Diagnostics, serves as on the Board of Directors and as a consultant for this organization, and owns Delfi Diagnostics stock, which is subject to certain restrictions under university policy. Additionally, Johns Hopkins University owns equity in Delfi Diagnostics. V.E.V. divested his equity in Personal Genome Diagnostics (PGDx) to LabCorp in February 2022. V.E.V. is an inventor on patent applications submitted by Johns Hopkins University related to cancer genomic analyses and cell-free DNA for cancer detection that have been licensed to one or more entities, including Delfi Diagnostics, LabCorp, Qiagen, Sysmex, Agios, Genzyme, Esoterix, Ventana and ManaT Bio. Under the terms of these license agreements, the University and inventors are entitled to fees and royalty distributions. V.E.V. is an advisor to Danaher, Takeda Pharmaceuticals, and Viron Therapeutics. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies.